A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3030-3030
◽
2006 ◽
Vol 24
(5)
◽
pp. 413-421
◽
2008 ◽
Vol 26
(4)
◽
pp. 347-354
◽